Trial of Lixisenatide in Early Parkinson's Disease

What Was Tested

The paper reports a study of Lixisenatide in the context of parkinson's disease, published as a randomized controlled trial.

Who Took Part

The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Lixisenatide group and the comparison group should start out alike.

As a double-blind Lixisenatide study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Lixisenatide, giving a reference point.

In this phase 2, double-blind, randomized, placebo-controlled trial, the researchers assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease.

What Was Measured

The subject headings attached to it are Antiparkinson Agents, Persons with Disabilities, Motor Disorders, Parkinson Disease, Peptides, Glucagon-Like Peptide-1 Receptor Agonists and Disease Progression.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Lixisenatide in people with parkinson's disease.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (The New England journal of medicine), a journal based in United States.

More context: the Lixisenatide compound page, Parkinson's disease research.